Illumina to cut $100M in fiscal 2025 costs

Illumina to cut $100M in costs to cope with China ban
The San Diego company also lowered its financial guidance for 2025 in response to China’s import restrictions.
Diagnostic Kit Maker Illumina To Cut $100 Million In Costs, Lowers 2025 Profit Outlook Amid China Trade Restrictions
Illumina slashes costs by $100 million after China bans its sequencers. The company lowers its 2025 EPS outlook and aims for high-single-digit growth by 2027.
Illumina aims to cut $100M in costs following China import ban
Illumina will seek to cut $100 million in expenses by the end of this fiscal year as it plans to deal with a loss of revenue from China, after the country banned the importation of its DN | Illumina also lowered its annual financial forecast,
Illumina lowers guidance, cuts spending to mitigate China ban on its gene sequencers
Illumina lowered its adjusted profit outlook and cut spending cost for 2025 as the company grapples with Chinese ban on its gene sequencers. Read more here.
China bans imports of Illumina's gene sequencers right after Trump tariff action
China announced a ban on Tuesday on imports of genetic sequencers from U.S. medical equipment maker Illumina, just minutes after U.S. President Donald Trump's additional 10% tariff on Chinese goods took effect.
Illumina to Cut $100 Million in Costs, Lowers Guidance Because of China Sales Ban
Illumina is reducing its forecast for this year’s financial performance and cutting $100 million in spending because China barred sales of the company’s gene-sequencing machines. San Diego-based Illumina is lowering its 2025 guidance to $4.
Why Illumina, Inc. (ILMN) Is Plunging So Far In 2025
We recently published an article titled Why These 15 Large-Cap Stocks Are Plunging So Far In 2025. In this article, we are ...
Illumina Inc. stock outperforms competitors on strong trading day
Shares of Illumina Inc. ILMN rose 2.33% to $86.62 Friday, on what proved to be an all-around positive trading session for the ...
Illumina price target lowered to $128 from $247 at RBC Capital
RBC Capital lowered the firm’s price target on Illumina (ILMN) to $128 from $247 but keeps an Outperform rating on the shares. The company’s ...
What Makes Illumina (ILMN) an Attractive Opportunity?
Brown Advisors, an investment management company, released its “Brown Advisors Global Leaders Strategy” fourth quarter 2024 ...
Illumina Inc. stock underperforms Thursday when compared to competitors
The stock's fall snapped a two-day winning streak.
China Targets San Diego Biotech Firm in Broadening Blacklist
In a sign it is willing to go further in responding to President Trump’s tariffs, Beijing blocked more American companies ...
Illumina addresses recent developments in China
Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today responded to the March 4, 2025 notice from the China Ministry of Commerce ("MOFCOM") that Illumina is not permitted to export ...